Mastering T cells to cure patients with solid tumors

  • FOUNDER'S VISION

    A message on the evolution of cancer treatment, Lyell’s commitment to scientific innovation, and how we are working toward our goal of curative cell therapy for any solid tumor.

  • OUR TEAM

    We have assembled a world-class team, including some of the foremost scientific leaders in the fields of oncology and adoptive cell therapy (ACT).

  • OUR TECHNOLOGY PLATFORMS

    We are applying Gen-R and Epi-R, our proprietary genetic and epigenetic reprogramming technologies, to overcome two major barriers to successful ACT – T cell exhaustion and lack of durable stemness.

  • OUR PIPELINE

    We are developing a multi-modality product pipeline. Each of our programs provides opportunities to expand into additional indications beyond those initially targeted.

  • News

    06.16.21

    Lyell Immunopharma Announces Pricing of Initial Public Offering

  • JOIN US

    Join a team of pioneers courageously striving for ambitious goals: cell therapies that eradicate solid tumors. Let’s do it together.